Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dipyridamole echocardiography

Dipyridamole echocardiography test (DET) has gained acceptancedue to its safety, feasibility, diagnostic accuracy and prognosticpower. The main limitation of the test is a less than idealsensitivity in some patient subsets, such as those with limitedcoronary artery disease. Atropine with dipyridamole might theoreticallycombine to become a synergistic ischaemic stress test, by increasingmyocardial oxygen demand through chronotropic stress and byreducing flow supply through a shortening of the diastolic intervalunder maximal coronary vasodilation. The aim of this study wasto assess the effects of the addition of atropine to DET. Threehundred and twenty-one patients (age=58±9 years), referredfor testing in the echo lab, were initially studied by DET.Of these, 151 were stopped during or within the 2 min followingdipyridamole infusion because of achievement of a predeterminedend-point: obvious echocardiographic positivity (n = 137), severechest pain (n = 3), diagnostic ST segment changes (n = 7) orlimited side effects (n = 4). In another three cases, atropinewas not given due to a history of glaucoma or severe prostatichypertrophy. In the remaining 167 patients with a negative DETtest, atropine (0.25 mg intravenously, repeated every min upto a maximum of 1 mg, if necessary) was added, starting 3 minafter the end of the dipyridamole infusion. The dipyridamole-atropineecho test (DETA) was positive in 32 and negative in 135 patients,and no major side effects occurred in any patient. The peakheart rate was significantly higher during DETA than with DETalone (108±16 vs 86±14 beats . min^–1; P<0.0001).In the subset of 178 patients who were studied while not takingantianginal therapy, who had no prior myocardial infarctionor revascularization procedure and who underwent coronary catheterization,independently of the test results, coronary angiography showednormal coronary arteries in 48 patients and significant coronaryartery disease (CAD) ( 50% luminal reduction in at least onemajor coronary vessel by quantitative coronary arteriography)in 130 patients—with single-, double- and triple-vesseldisease in 56, 47 and 27 patients, respectively. The sensitivitywas 96/130 for DET and 110/130 for DETA (72 vs 85%, P<0.01)while the specflcity was 96% and 92% (P=ns), respectively. Theaddition of atropine to dipyridamole, which causes further chronotropicstress to the myocardium already challenged by flow maldistribution,is well tolerated and safe, and increases the sensitivity ofthe test for the detection of coronary artery disease with noloss in specificity.